Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Shahin Jamal"'
Autor:
Sabrina Hoa, Alexandra Saltman, Shahin Jamal, Carrie Ye, Janet E. Pope, Annaliese Tisseverasinghe, Megan E. Himmel, Aurore Fifi-Mah, Janet Roberts, Robert Rottapel, Marie Hudson, Daniel Ennis, Nancy Maltez
Publikováno v:
Autoimmunity reviews. 19(8)
Objective Although immune checkpoint inhibitors (ICI) have revolutionized cancer therapy, their use is associated with immune toxicities referred to as immune-related adverse events (irAE). Here we describe the clinical presentation and management of
Publikováno v:
Modern Rheumatology Case Reports. 2:80-83
Isolated pulmonary capillaritis (IPC) is a rare autoimmune cause of diffuse alveolar haemorrhage (DAH), diagnosed by histopathological evidence of lung capillaritis in the absence of system...
Publikováno v:
Abstracts Accepted for Publication.
Background Immune checkpoint inhibitors (ICI) have revolutionized the treatment of cancer. However, enhanced immune activation from ICI has been associated with immune-related adverse events (irAE), including autoimmune rheumatologic diseases such as
Publikováno v:
THURSDAY, 14 JUNE 2018.
Background Immune checkpoint inhibitors (ICI) have made a significant impact on the treatment of many advanced malignancies. There is little data on the rheumatologic complications of these treatments. Objectives We describe 12 cases of rheumatologic
Autor:
D. Lin, Edward C. Keystone, Shahin Jamal, J. Carter Thorne, Janet E. Pope, Diane Tin, Gilles Boire, Vivian P. Bykerk, Glen Hazlewood, Carol A. Hitchon, Boulos Haraoui
Publikováno v:
Annals of the Rheumatic Diseases. 75:1003-1008
ObjectiveTo determine the comparative effectiveness of oral versus subcutaneous methotrexate (MTX) as initial therapy for patients with early rheumatoid arthritis (ERA).MethodsPatients with ERA (symptoms ≤1 year) initiating MTX therapy were include
Autor:
Jason J. Lee, Vivian P. Bykerk, Shahin Jamal, Diane Tin, Gilles Boire, Carter Thorne, George K. Dresser, Boulos Haraoui, Carol A. Hitchon, Edward C. Keystone, Janet E. Pope
Publikováno v:
Clinical Medicine Insights. Arthritis and Musculoskeletal Disorders
Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders, Vol 2016, Iss 9, Pp 37-43 (2016)
Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders, Vol 9 (2016)
Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders, Vol 2016, Iss 9, Pp 37-43 (2016)
Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders, Vol 9 (2016)
Objectives The mechanism of action of methotrexate in rheumatoid arthritis (RA) is complex. It may increase adenosine levels by blocking its conversion to uric acid (UA). This study was done to determine if methotrexate lowers UA in early RA (ERA). M
Publikováno v:
The Journal of Rheumatology. 38:289-296
Objective.Biologic agents are increasingly used in the rheumatic diseases. Their role in patients with systemic sclerosis (SSc) is uncertain. Our aim was to evaluate the effectiveness and safety of biologic agents in SSc. We review the evidence for t
Publikováno v:
Clinical Rheumatology. 28:413-419
In recent years, there has been a shift in the therapeutic approach to rheumatoid arthritis (RA), with emphasis on early therapy. The DE019 trial demonstrated adalimumab efficacy in patients with RA. This subanalysis compares response to adalimumab b
Autor:
E.C. Keystone, Diane Tin, D. Lin, Boulos Haraoui, Vivian P. Bykerk, B. Aberumand, Gilles Boire, Janet E. Pope, Carol A. Hitchon, Carter Thorne, Shahin Jamal, Orit Schieir
Publikováno v:
Annals of the Rheumatic Diseases. 75:683.2-684
Background Rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPA) status may affect treatment response in early rheumatoid arthritis (ERA). Objectives To investigate differences in treatment response to disease modifying anti-rheumat
Autor:
Cheryl Barnabe, Robert Offer, Anthony S. Russell, Kam Shojania, Boulos Haraoui, Vandana Ahluwalla, Wojciech P. Olszynski, Shahin Jamal
Publikováno v:
Clinical rheumatology. 31(9)
We have reviewed the issues surrounding the advent of biosimilars in the rheumatoid arthritis biologic field. Our proposals emphasize the need to focus primarily on patient safety and to assess the outcomes of therapy both in the short and longer ter